US Stock Insider Trading | Equillium disclosed 4 insider transactions on February 23

2026-02-23 23:14:20

On February 23, 2026, Equillium (EQ) disclosed four insider trading transactions. Executive Zedelmayer Christine purchased 109,400 shares on February 19, 2026.

[Recent Insider Transactions]

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share/USD	Total Amount/USD
February 23, 2026	Executive	Zedelmayer Christine	February 19, 2026	Buy	76,600	0.73	5,590
February 23, 2026	Executive	Zedelmayer Christine	February 19, 2026	Sell	76,600	1.74	133,300
February 23, 2026	Executive	Zedelmayer Christine	February 19, 2026	Buy	109,400	0.79	85,900
February 23, 2026	Executive	Zedelmayer Christine	February 19, 2026	Sell	109,400	1.78	194,800
January 9, 2026	Executive	Tom Penny	January 8, 2026	Sell	6,533	1.29	8,427.57
December 23, 2025	Executive	Zedelmayer Christine	December 23, 2025	Buy	100,000	0.79	7,850
December 23, 2025	Executive	Zedelmayer Christine	December 23, 2025	Sell	100,000	1.50	150,000
December 15, 2025	Executive	Zedelmayer Christine	December 12, 2025	Sell	23,800	1.34	31,900
December 15, 2025	Executive	Zedelmayer Christine	December 15, 2025	Sell	11,900	1.31	15,600
November 25, 2025	Executive	Zedelmayer Christine	November 25, 2025	Sell	100	0.98	98.00

[Company Information]

Equillium, Inc. was incorporated on March 16, 2017, in Delaware. The company was formerly known as Attenuate Biopharmaceuticals, Inc. It is a clinical-stage biotechnology company that leverages a deep understanding of immunobiology to develop novel therapies for serious autoimmune and inflammatory diseases with high unmet medical needs. The company’s strategy focuses on advancing candidate products through clinical development, potentially seeking additional indications, and acquiring new candidates and platforms to expand its pipeline. The company plans to commercialize its candidates independently or through partnerships, or monetize its pipeline through strategic transactions.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.